Review Article Open Access

A Novel Drug for Refractory Diffuse Large B-Cell Lymphoma (DLBCL)- A Review

Abstract

Epkoritamab, a subcutaneously injected CD3xCD20 T cell receptor, is the first and only bispecific antibody that activates T cells, directing them to attack CD20+ B cells. It has been shown to increase immune response in DLBCL, FL and patients. MCL regardless of previous CD20 monoclonal antibody therapy. Its mechanism of action differs from other immunotherapy, such as CAR T cell therapy, which involves genetic modification of the patient's own T cells for cancer cells. FDA grants accelerated approval for epcoritab-bysp (Epkinly) as a third-line treatment for relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) of undetermined origin, including DLBCL and grade B cells caused by indolent lymphoma after two or more lymphomas gave many treatments. Non-Hodgkin Lymphoma (NHL) is a type of Large B-Cell Lymphoma (DLBCL). It is a cancer of the lymphatic system that occurs when the body produces abnormal B lymphocytes, which are white blood cells that normally help the body fight disease. There are several subtypes of DLBCL, including Central Nervous System (CNS) primary DLBCL, DLBCL not otherwise specified (NOS), and primary mediastinal (thymic) large B-cell lymphoma. DLBCL is usually treated with different types of chemotherapy, steroids, and a monoclonal antibody called rituximab. The R-CHOP regimen, representing rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, is effective in approximately 60% of patients and can eliminate the disease. But DLBCL can come back after treatment, and researchers are working to better understand the basis of the disease to develop new treatments and improve treatment outcomes. In this review, we discuss the expansion of epkoritamab in the treatment of refractory DLBCL.

Ancy Chacko*, Jibin James, Ansu Chacko

To read the full article Download Full Article